News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 23, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the...
-
Oct 17, 2017Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced financial results for the third quarter ending...
-
Oct 16, 2017Trial supported by a $16M non-dilutive grant from CIRM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral...
-
Oct 3, 2017Conference Call and Live Webcast at 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months...
-
Sep 27, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017...
-
Aug 15, 2017Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
-
Aug 14, 2017Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
- Aug 10, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and six months ended
-
Aug 7, 2017Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advocacy at Bristol-Myers Squibb Company
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the...
-
Jul 25, 2017
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the
